IDH2 and acute myeloid leukemia: The persistence of IDH1/2 mutations (especially IDH2 R140Q) in remission was observed in 7–39% of AML cases in the literature, [19, 44–46] which is in line with our study (24% of IDH1 or IDH2 mutations were detectable in complete remission with a higher than 2.5% VAF, 67% of persisting mutations was IDH2 R140Q).